Clinical Utility of Fluorescence In Situ Hybridization for Prediction of Residual Tumor After Transurethral Resection of Bladder Urothelial Carcinoma (Q44736576)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 5, 2011

Language	Label	Description	Also known as
English	Clinical Utility of Fluorescence In Situ Hybridization for Prediction of Residual Tumor After Transurethral Resection of Bladder Urothelial Carcinoma	scientific article published on February 5, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Clinical utility of fluorescence in situ hybridization for prediction of residual tumor after transurethral resection of bladder urothelial carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Clinical Utility of Fluorescence In Situ Hybridization for Prediction of Residual Tumor After Transurethral Resection of Bladder Urothelial Carcinoma (English)

1 reference

10.1016/J.UROLOGY.2010.09.061

https://api.crossref.org/works/10.1016/J.UROLOGY.2010.09.061

23 November 2024

fluorescence in situ hybridization

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21296388

23 November 2024

author name string

Tao Ding

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Yin-Kui Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

You-Han Cao

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Luo-Yan Yang

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

5 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0090429510019473?httpAccept=text/xml

1 reference

10.1016/J.UROLOGY.2010.09.061

https://api.crossref.org/works/10.1016/J.UROLOGY.2010.09.061

23 November 2024

https://api.elsevier.com/content/article/PII:S0090429510019473?httpAccept=text/plain

1 reference

10.1016/J.UROLOGY.2010.09.061

https://api.crossref.org/works/10.1016/J.UROLOGY.2010.09.061

23 November 2024

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

77

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

855-859

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

The value of a second transurethral resection for T1 bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

A re-staging transurethral resection predicts early progression of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

"Complete transurethral resection of bladder tumor": are the guidelines being followed?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

DNA-based molecular cytology for bladder cancer surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

The value of a second transurethral resection in evaluating patients with bladder tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

Should we abandon the FISH test?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.09.061

7 January 2021

urinary bladder

13

1 reference

10.1016/J.UROLOGY.2010.09.061

https://api.crossref.org/works/10.1016/J.UROLOGY.2010.09.061

23 November 2024

Identifiers

10.1016/J.UROLOGY.2010.09.061

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44736576&oldid=2278799069"